| Ticker: | CRBP |
| Current Price: | $3.39 |
| % Daily Change: | -0.59% |
| Volume (1,000s): | 573.37 |
| Average Volume (1,000s): | 503.42 |
| Market Cap (M): | $69.86 |
| 1/2/2024 Price: | $6.04 |
| Change Since Inception: | -43.87% |
Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062
United States
We are focused on connecting innovation to purpose.
Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin 4-on cancer cells to release a cytotoxic payload and CRB-601, and anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells.